On March 20, 2024, RetinalGenix Technologies Inc. closed the transaction. The transaction included participation from 25 investors. The company paid $3,500,000 as sales commissions in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8357 USD | -11.65% | -19.64% | -3.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.69% | 31.43M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. announced that it has received $50 million in funding